
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 68.2 kDa. The protein migrates as 80-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human TrkA (33-417), Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Immobilized Human Beta-NGF Protein, premium grade (Cat. No. BEF-H5214) at 1 μg/mL (100 μL/well) can bind Human TrkA (33-417), Mouse IgG2a Fc Tag (Cat. No. TRA-H5259) with a linear range of 0.1-16 ng/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma | Details |
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Mainland China | Solid tumours | Roche (China) Holding Ltd | 2019-06-18 | Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Cholangiocarcinoma; Solid tumours; Central Nervous System Neoplasms; Neuroendocrine Tumors; Salivary Gland Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Skin Melanoma | Details |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | Mainland China | Solid tumours | Bayer Healthcare Company Ltd | 2018-11-26 | Endometrial Neoplasms; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytosis, Langerhans-Cell; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Lung Neoplasms; Uterine Neoplasms; Osteosarcoma; Lymphoma; Lymphoma, Non-Hodgkin; Glioma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Esophageal adenocarcinoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Xanthogranuloma, Juvenile; Uterine Cervical Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Rectal Neoplasms; Fibrosarcoma; Rhabdomyosarcoma; Liver Neoplasms; Leukemia; Ovarian Neoplasms; Medulloblastoma; Solid tumours; Hepatoblastoma; Rhabdoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ependymoma; Stomach Neoplasms; Skin Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Multiple | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| AK-1830 | AK-1830 | Phase 1 Clinical | Array Biopharma | Inflammation | Details |
| XZP-5955 | XZP-5955 | Phase 2 Clinical | Solid tumours | Details | |
| ACD-856 | ACD-856 | Alzecure Pharma Ab | Details | ||
| VM-902A | VM-902; VM-902A | Vm Discovery | Details | ||
| TQB-3558 | TQB-3558 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | Details |
| SNA-125 | CT-340; SNA-125 | Phase 2 Clinical | Sienna Biopharmaceuticals Inc, Creabilis Sa | Pruritus; Psoriasis; Dermatitis, Atopic | Details |
| VMD-928 | VMD-928 | Phase 1 Clinical | Vm Oncology Llc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Adenoid Cystic; Mesothelioma; Prostatic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| PBI-200 | Phase 2 Clinical | Pyramid Biosciences | Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms | Details | |
| HH-30134 | HH-30134 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| FCN-098 | FCN-098; FCN098 | Phase 1 Clinical | Fochon Pharmaceuticals Ltd, Fochon Pharmaceuticals Ltd | Solid tumours; Neoplasms | Details |
| BEN-2293 | BEN-00002293; BEN-2293 | Phase 2 Clinical | Benevolentai Bio Ltd | Dermatitis, Atopic | Details |
| VC-004 | VC-004; VC 004; VC004 | Phase 2 Clinical | Jiangsu Vcare Pharmatech Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.




